Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. See why NVO stock is a Buy.

Pharmaceutical company Novo Nordisk has launched its mega-popular weight-loss drug Wegovy in China — but for a tiny fraction ...

We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...

Uptake of continuous glucose monitoring (CGM) was relatively low among vulnerable diabetes patients in the largest national ...

Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

Until recently, no other drug had come close to producing the same level of weight loss as semaglutide - creating an ...

There have been 274 hospitalisations associated with weight-loss injections - far higher than the 68 previously detailed by ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Scientists have uncovered a biological explanation for the frustrating phenomenon known as the "yo-yo effect" -- the memory of your fat cells.